Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

Given the late-breaking data on topical ruxolitinib's effectiveness in prurigo nodularis and its rapid itch relief, how do you foresee this impacting treatment paradigms for chronic pruritic ...

Where does prurigo nodularis develop on the body? Prurigo nodularis causes itchy bumps on the skin, which appear when someone repeatedly scratches, picks at, or rubs their skin. These itchy bumps, ...

The global prurigo nodularis treatment market is poised for substantial growth, projected to reach a valuation of USD 693.3 million by 2023, according to a recent report by Future Market Insights. The ...

Acute prurigo usually does not require extensive additional examinations. Its treatment must be guided according to the causative agent. Treatment is symptomatic: non-sedating antihistamines (anti-H1) ...

Prurigo nodularis (PN) is a chronic (long-term) skin condition that causes intense itching and firm bumps on the outer layer of the skin, known as nodules. As a result of the itching, some people also ...

The Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab-ilto) for the treatment of adults with prurigo nodularis.

"The U.S. FDA's rapid approval of Nemluvio in prurigo nodularis is a first step in achieving its blockbuster platform potential and reinforces our leadership in therapeutic dermatology. We're ...